ArticleWorld journal of surgical oncology2024
Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study.
Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does adjuvant therapy improve survival in patients undergoing pancreaticoduodenectomy for distal cholangiocarcinoma? A systematic review, meta-analysis and meta-regression.Updates in surgery · 2026Pooled it
- Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer?Annals of surgical oncology · 2026Article
- Area-based centralization of pancreatic surgery: a Hub-and-Spoke system balances patient proximity and quality of care.Updates in surgery · 2026Article
- Article
- Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges.Journal of thrombosis and thrombolysis · 2026Review
- TNM stage I pancreatic ductal adenocarcinoma patients without pathological risk may drive limited benefit from adjuvant chemotherapy.Frontiers in medicine · 2026Article
- Initiation and Completion of Adjuvant Chemotherapy After Total Versus Partial Pancreaticoduodenectomy for Pancreatic Cancer.Annals of surgical oncology · 2025Article
- Rethinking resectability: the case for neoadjuvant treatment in resectable pancreatic cancer.Hepatobiliary surgery and nutrition · 2025Article
- Sequence of Chemotherapy May Not Impact Survival After Resection of Pancreatic Tail Adenocarcinoma.Journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant chemotherapy (AC) improves the prognosis after pancreatic ductal adenocarcinoma (PDAC) resection. However, previous studies have shown that a large proportion of patients do not receive or complete AC. This national study examined the risk factors for the omission or interruption of AC.
methodsData of all patients who underwent pancreatic surgery for PDAC in France between January 2012 and December 2017 were extracted from the French National Administrative Database. We considered "omission of adjuvant chemotherapy" (OAC) all patients who failed to receive any course of gemcitabine within 12 postoperative weeks and "interruption of AC" (IAC) was defined as less than 18 courses of AC.
resultsA total of 11 599 patients were included in this study. Pancreaticoduodenectomy was the most common procedure (76.3%), and 31% of the patients experienced major postoperative complications. OACs and IACs affected 42% and 68% of the patients, respectively. Ultimately, only 18.6% of the cohort completed AC. Patients who underwent surgery in a high-volume centers were less affected by postoperative complications, with no impact on the likelihood of receiving AC. Multivariate analysis showed that age ≥ 80 years, Charlson comorbidity index (CCI) ≥ 4, and major complications were associated with OAC (OR = 2.19; CI
conclusionSequence surgery followed by chemotherapy is associated with a high dropout rate, especially in octogenarian and comorbid patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.